Drug repurposing for respiratory infections

Area of Science:

• Infectious Diseases
• Pharmacology
• Drug Discovery

Background:

• Respiratory infections, including Coronavirus disease 2019, pose significant global health risks, particularly for vulnerable populations.
• Traditional drug development is hampered by long timelines, high costs, and increasing antimicrobial resistance.

Purpose of the Study:

• To review the progress and challenges in repurposing drugs for respiratory infections.
• To highlight the potential of drug repurposing as an efficient therapeutic strategy.

Main Methods:

• Summarizing current advancements in drug repurposing for respiratory infections.
• Exploring computational methods, high-throughput screening, and preclinical studies for candidate identification.
• Examining regulatory aspects and clinical trial designs for repurposed drugs.

Main Results:

• Identified notable examples of repurposed drugs and their mechanisms of action.
• Emphasized the role of computational and screening approaches in identifying viable drug candidates.
• Highlighted the importance of regulatory pathways and clinical validation for repurposed therapies.

Conclusions:

• Drug repurposing is a valuable and efficient method to expand treatment options for respiratory infections.
• This strategy can lead to improved patient outcomes and reduce the global burden of disease.
• Further research and clinical validation are crucial for successful implementation.